Hemp CBD Products Offer a Natural Alternative to Synthetic-Derived Medicines

CannabisNewsWire Editorial Coverage: The opioid crisis in North America has drawn attention to the urgent need for alternative medicines, and hemp CBD products offer a viable plant-based option.

  • An active ingredient in industrial hemp, Cannabidiol (CBD) can be extracted to be used in a number of different products such as topicals, tinctures, and capsules.
  • The World Health Organization (WHO) has found CBD to be nonpsychoactive, nonaddictive, and to have a positive effect on patients’ health.
  • Scientific studies have shown CBD to be effective in pain relief and, therefore, it may be a healthier alternative to addictive opioids.

Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) is actively engaged in producing all-natural products containing CBD, including a recently released pain cream that can be applied topically to relieve discomfort. Cronos Group, Inc. (NASDAQ: CRON) has recently received a boost in funds and a license to produce cannabis products in Australia, allowing the company to grow its operations. Canopy Growth Corporation (NYSE: CGC), which produces oils containing CBD, is expanding into Lesotho and Colombia, exploring a global pain-relief market. Aurora Cannabis, Inc. (OTCQX: ACBFF), which already produces a wide range of medical marijuana strains, is in the process of acquiring an R&D company to strengthen its offerings. And Organigram Holdings, Inc. (OTCQB: OGRMF) produces medical strains that include a CBD option for patients and care providers eager to benefit from this ingredient.

The Opioid Epidemic

The United States is facing one of its greatest medical crises in decades — the opioid epidemic. During 2016 alone, 42,249 people died of opioid overdoses, 115 deaths every day. Despite the attention being turned onto this problem, most states are seeing further increases rather than declines in opioid abuse and its consequences. As the problem grows, physicians, emergency rooms and other healthcare providers are feeling pressure to find effective treatments for pain management, one of the largest causes of the growing problem.

Though illegal drugs such as heroin play their part, this crisis is fuelled by prescription drugs. The prescription painkiller problem began in the 1990s, when pharmaceutical companies persuaded healthcare providers that they could prescribe opioid painkillers without risk of addiction. This proved to be untrue, as large numbers of patients began misusing the drugs. Today, an estimated 21–29 percent of patients prescribed opioids misuse them, with 8–12 percent developing a disorder. And while misuse of legal drugs is a huge problem in its own right, it is also the gateway to illegal opioids. However, by the time the problem was recognized, the medical sector had become reliant on opioids. Pain relief is a critical part of modern medicine, which helps patients manage chronic conditions as well as cope with recovery from shorter-term illnesses, accidents and operations. Simply abandoning opioids was not an option.

An Alternative to Opioids

One option gaining increased attention may be the use of all-natural cannabidiol (CBD) products, as a plant-derived option to the use of synthetic prescription painkillers. These products do not contain THC, the ingredient that gets cannabis users high, and so can be used to provide relief without impairing a user’s normal mental activities. Products containing CBD, which have recently been developed by companies such as Marijuana Company of America (MCOA Profile), may offer a viable alternative to synthetic medicines.

CBD applications and uses have benefitted from changes surrounding that industry. Licenses  to grow industrial hemp have allowed companies to combine agriculture, R&D and product development with those seeking medical uses for hemp. MCOA’s recently established cultivation in Oregon is a prime example of this work, with researchers developing better growing techniques and improved plant strains that will allow them to extract higher yields of CBD oil.

A Healthier Option?

Scientific research into the effectiveness of CBD supports its potential in pain relief. A review of recent studies found that it was generally effective in helping patients manage their pain. Not only can it provide a viable alternative to opioid painkillers.

The advantage of CBD over opioids appear to be that it may provide a safer, healthier treatment option. CBD appears to be far less physically and mentally addictive than many prescribed pain medications. Patients can use it without experiencing the high risks of addiction that accompany many prescription painkillers.

The World Health Organization released a scientific research report conducted on CBD, which found the compound to be nonpsychoactive and nonaddictive; the report also noted that it has multiple health benefits. CBD oils provide patients with access to the relief that medical marijuana would bring but without many of the side effects.

Applied Medicine

By providing alternatives for relief, companies working with CBD are providing a pathway out of the opioid epidemic. One example of a CBD pain-management product is MCOA’s recently released hempSMART Pain Cream.

HempSMART Pain Cream is a topical treatment developed to reduce discomfort, support joint mobility, and relax muscles. Each bottle contains 300mg of full-spectrum CBD derived from industrial hemp, combined with other natural plant-based extracts. The cream contains the company’s own formulation of Ayurvedic herbs along with menthol, cayenne pepper extract, rosemary oil, aloe gel, white willow bark, arnica, wintergreen extract and tea tree oil. Together, these ingredients appear to provide an immediate cooling and soothing sensation, while the CBD helps to ease discomfort.

“We will continue to expand our health and wellness lines in 2018 to include more products,” said MCOA CEO Donald Steinberg. “Pain Cream has been enthusiastically received by our affiliates and customers.”

Pain Cream is just one of many hempSMART products already developed by MCOA. As more is learned about the potential uses of CBD in wellness products, the company will likely develop new products and treatments. From hempSMART Brain, a brain-enhancing formulation, to hempSMART Face, a CBD-infused cosmetic, the company is finding new ways to deliver the benefits of this chemical compound.

Cannabis Companies Explore Potential of CBD

Meanwhile, patients looking for pain relief have the chance to move away from prescription drugs and into treatments without the same risks of addiction. A number of other companies are also exploring the potential of CBD treatments.

One of the most prominent is Cronos Group, Inc. (NASDAQ: CRON), the first Nasdaq-traded company purely focused on cannabis. Though based in North America, the company has recently started branching out, obtaining a manufacturing license to produce products based on medical cannabis in Australia. Boosted by funds raised through a recent public offering, the company is set to become a global player in the field of cannabis-derived treatments, including pain medication.

Canopy Growth Corporation (NYSE: CGC) is also looking to bring cannabis and CBD treatments to a wider market. Having previously acquired a cannabis company in Lesotho, giving it access to the African market, the company is now expanding into Latin America through the acquisition of a Colombian company. Canopy Growth produces oils with varying levels of CBD to meet the varying needs of customers.

One of the world’s largest cannabis companies, Aurora Cannabis, Inc. (OTCQX: ACBFF) is heavily involved in pain relief through its wide selection of medical cannabis strains. The company recently took a step toward improving its research into cannabis-derived medicine, thanks to the Canadian Competition Bureau’s approval of a proposed takeover of MedReleaf. By acquiring another R&D-driven cannabis company, Aurora hopes to expand its own research into CBD-based medicines.

Medical cannabis company Organigram Holdings, Inc. (OTCQB: OGRMF) has produced a range of different strains, including CBD-rich options. It has recently been licensed to expand its production facilities, allowing the company to better meet the needs of a growing market.

With companies developing hemp-derived, CBD-based wellness products, a new alternative to synthetic opioid-based medications is emerging. CBD-based options may also provide access to the benefits of medical cannabis without that product’s mind-altering properties and other worrisome side effects.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Cannabidiol Market Anticipates Growth as Regulatory Change Looms in U.S.

CannabisNewsWire Editorial Coverage: Restrictions in the United States on cannabidiol (CBD), an active ingredient in cannabis, appear likely to loosen over the next few months, creating opportunities for CBD production and distribution companies.

  • CBD is an active ingredient with medical benefits but no “high”, or pyshcoactive effects.
  • The Food and Drug Administration (FDA) has approved a CBD-based medicine for the first time.
  • Companies are cultivating hemp to develop high yielding CBD plants.

Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is cultivating industrial hemp for CBD  propagation at sites in the United States and Canada while continuting to develop and manfuacture CBD-based products for its hempSMART™ brand. Cronos Group, Inc. (NASDAQ: CRON) is expanding its global reach for cannabis products through deals covering the United States, Canada, Australia and Poland, as this sector of the economy goes global. CV Sciences, Inc. (OTC: CVSI) is providing a clean bill of health for its CBD wellness products. Terra Tech Corp. (OTC: TRTC) is providing advanced hydroponic growing systems that increase crop yields and reduce costs for CBD-oriented companies. Manufacturer Liberty Health Sciences (OTC: LHSIF) produces cannabis in facilities recently certified as meeting high standards for manufacturing.

FDA Leads the Way to Reclassify Cannabidiol

The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks. For the first time, the FDA has approved a medicine that uses cannabidiol (CBD) as its active ingredient. CBD is a compound that can be found in the hemp and cannabis plants, but unlike tetrahydrocannabinol (THC) it does not get users high.

Repeated studies have demonstrated the beneficial effects of cannabinoids. As a result, cannabis products have been approved for medical use in many states, but this is the first time that a cannabinoid-based CBD product has been approved at the federal level. This approval represents a softening of the federal government’s attitude. CBD was previously classified as a Schedule I drug by the Drug Enforcement Agency, but this body is now expected to change its stance within the next three months, allowing the possibility to manufacture products that would currently be banned on the national level. This possibility represents a huge moment for the CBD industry.

Better Plants for Better Health

One of the companies likely to benefit from this change is the Marijuana Company of America, Inc. (OTC: MCOA). The company is focused on the cultivation of industrial hemp and the manufacturing of hemp-derived CBD products, and is expanding its operations to better serve its growing market.

The most recent addition to the company’s operations is an industrial hemp cultivation site in Scio, Oregon. Created in collaboration with Global Hemp Group (GHG), this is a 109-acre site in the Willamette Valley. With its rich soil and pre-existing irrigation infrastructure, the valley provides an ideal location for an agricultural project that has already been home to cannabis cultivation in the past.

The Scio facility uses a mixture of cultivation practices. It has 19,000 square feet of greenhouse growing space under construction alongside fields for outdoor crops. This will allow the company to produce a steady supply of hemp all year, with high-yield plants ensuring a significant volume of output.

One of the main aims of the team working at Scio is to encourage plant strains that have a particularly high yield of CBD. Careful data collection and analysis are being used to assess the quality of plants and the effectiveness of techniques used to grow them. The expected change in the legal status of CBD in the United States will make it easier for MCOA to conduct research and cultivate CBD rich industrial hemp like at the Scio site, and for patients to have access to the products that come from it.

Working with Government to Improve Agriculture

MCOA and GHG are also collaborating on a similar project in New Brunswick, Canada, on a much larger scale. For this project, the two companies are working with the New Brunswick Department of Aquaculture, Agriculture and Fisheries (DAAF) to explore better approaches to growing hemp.

With markets for hemp and CBD reaching greater maturity, the DAAF has shown its faith in the future by awarding a grant of $10,750 to the joint MCOA and GHG venture in the region. These funds will be used on test projects for the current crop season, which will allow the companies to improve their cultivation techniques.

These government-funded tests are focused on three areas, two of which are looking at soil conditions to identify the best levels of nitrogen fertilizer for crops and whether soil acidity can be effectively adjusted using local supplies of slag lime. The third area of study is the European corn borer, a moth that damages crops and that has been a pest to farmers in the region. Damage from borers was found on hemp stalks last year, so the companies will be looking at the impact this damage could have on cultivation.

The latest technology is being used to ensure the success of these tests. A drone company has been employed to provide overviews of growth across hemp fields because the height of the stalks and density of cultivation makes assessment by other means difficult. With agricultural experiments underway in both Canada and the United States, MCOA has multiple opportunities to cultivate better CBD crops.

In New Brunswick, the two companies have created what they refer to as the Hemp Agro-Industrial Zone (HAIZ), where they are carrying out trials of hemp cultivation targeted at developing the industry in the province. By exploring cultivation techniques, ensuring a market for the product and providing consistent jobs for local farm workers, they aim to create a green-industry cluster specializing in hemp.

Creating Wellness

MCOA isn’t just a cultivation company. It is manufacturing its hemp crops into a wide range of products formulated to improve the well-being of customers.

Much of this work is carried out through hempSMART, the company’s most prominent consumer brand. HempSMART creates CBD-based wellness products and provides consumers with education about the potential benefits CBD may provide. Many consumers don’t understand the difference between CBD and THC products. Through hempSMART, MCOA is raising awareness while reaching out to a growing market.

The most recent release from hempSMART is the relaunch of its hempSMART Brain product. This version doubles the dose of CBD from the original, combining CBD oil with a blend of natural plant-based ingredients. Designed to maintain mental clarity, alertness, focus and concentration, as well as promote relaxation, restorative sleep, and the repair and regeneration of brain cells, hempSMART Brain is a flagship product that demonstrates MCOA’s wellness agenda. With the prospect of a change in the CBD compound’s legal status in the United States, companies such as MCOA will have more opportunities to develop and sell these types of products, spreading CBD-based wellness.

Growing Companies Profit from Changing Regulations

A range of companies in the cannabinoid sector will be in a position to profit from this change. Cronos Group, Inc. (NASDAQ: CRON) is demonstrating the global potential of cannabinoid products. The North American company already has a cross-border deal that allows it to make use of advances in both Canada and the United States. In addition, Cronos was recently granted a manufacturing license to produce cannabis-based products in Australia, and a new Polish distribution agreement will give the company a foothold in the European market.

CV Sciences, Inc. (OTC: CVSI) is firmly focused on the CBD sector. The company has two parts: a drug development division exploring novel CBD-based treatments and a consumer product division that manufactures, markets and sells the resulting products.

Some companies are focused on providing support and equipment for CBD cultivation. Terra Tech Corporation (OTC: TRTC) has created a hydroponic growing system that uses moving tables to increase yields by up to 30 percent while reducing costs by up to half. Its energy efficiency and recycling of waste water means that the company’s systems live up to the expectations of green-minded consumers.

Liberty Health Sciences (OTC: LHSIF) works in the medical cannabis market. As it acquires and operates U.S.-based cannabis companies, its aim is to produce safe, high-quality cannabis for patients. It has recently received Good Manufacturing Practice certification for its high standards of safety, consistency and quality.

Given the growing number of players in the cannabis market, a shift in the classification of CBD on a federal level could have a tremendous impact. For companies already focusing on CBD products, a huge opportunity for growth in the United States may be on the horizon.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Farm Bill Legislation May Springboard Federal Hemp Acceptance

CannabisNewsWire Editorial Coverage: The United States House passed the 2018 Farm Bill, which will redefine subsidies to farmers, nutritional welfare recipients, conservationists and others. Tucked into this bill of more than 1,000 pages is hemp legalization legislation supported by Senate Majority Leader Mitch McConnell. Demand – and thus farming revenue – for tobacco is waning, and McConnell says hemp farming could help bolster farming communities in his home state of Kentucky and across the country. Currently listed as a controlled substance under federal law, the new bill will declassify hemp as a schedule 1 drug and label it as a viable agricultural commodity. Through its hempSMART™ subsidiary, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is one example of a few companies currently providing consumers hemp plant-based products under the rubric of existing laws, and the company has undertaken broad-based legal hemp cultivation programs. Other companies that could feel the ripples of change in the space are Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), Medical Marijuana, Inc. (OTC: MJNA), and Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) (LXRP Profile).

Hemp’s History

Archaeological evidence reveals that for over 10,000 years hemp has been used by humans for pottery, shoes, ropes, clothing, food, medicine, and a wide array of other applications. Since early populations ingested hemp seeds, it stands to reason they also discovered the medicinal properties found in the plant. Ancient Asia, Egypt, India, Greece and the Islamic world all have rich histories relating to medicinal cannabis. In the 19th century, cannabinoids gained popularity for therapeutic use in Western medicine, but regulatory efforts imposed strictures during the 20th Century, eventually leading to a ban on its use in the U.S. under federal drug controls because of hemp’s relation to its more drug-user-friendly cannabis counterpart, marijuana. But, in recent years, society has turned to modern science to substantiate anecdotal claims about the therapeutic efficacy of non-psychoactive cannabidiol (CBD) found in the hemp plant.

“I know there are farming communities all over the country who are interested in this,” McConnell told the Senate Agriculture Committee amid debate over his bill. “Mine are particularly interested in it, and the reason for that is — as all of you know — our No. 1 cash crop used to be something that’s really not good for you: tobacco. And that has declined significantly, as it should, given the public health concerns.”

The federal government has exhibited schizophrenic regulatory tendencies toward hemp since the passage of the Marijuana Tax Act of 1937 that quashed hemp production with exorbitant excise taxes.  Reversing course during WWII, the government urged farmers to grow hemp for fiber and also waived taxes, and over 400,000 acres of hemp were cultivated between 1942 and 1945. After the war, hemp again had persona non grata status. Congress then passed the Controlled Substances Act in 1970, prohibiting the use of all cannabis for any purpose whatsoever and effectively terminating all industrial hemp production. Hemp extracts, however, are considered legal because they contain less than 0.3 percent THC, but the cultivation of hemp remains federally verboten. Now, the advancement of the Farm Bill signals a revived federal interest in the industrial hemp industry.

Hemp Pioneers

Led by hemp industry pioneers, Marijuana Company of America, Inc. (OTC: MCOA) has spearheaded efforts and staked claims on multiple legal hemp cultivation projects. The company’s innovative strategy is to vertically integrate hemp production and sales – from seed to shelf. Cultivation of quality hemp will feed MCOA’s innovative CBD-based formulations, which use the highest-quality hemp to produce what could be the finest-quality botanical supplements on the market. The hempSMART™ product line contains tested levels of clinically researched ingredients to meet consumer needs that support the body’s natural endocannabinoid system.

From seed to shelf, MCOA has built its business model around industrial hemp-based CBD products. Hemp has a myriad of uses beyond CBD therapeutics – as a food, a natural fiber, and even as a commodity in the building materials sectors. No part of the plant goes unused, and MCOA’s overarching strategy is to capitalize at each profit point – from farm to finished products. MCOA appears to be establishing a commanding presence at multiple inflection points across the entire hemp value chain.

hempSMART™, Inc.

Expanding on ancestral wisdom, MCOA has combined the most effective ingredients in wellness technologies with pure plant-derived industrial hemp-based cannabinoids to create optimally formulated wellness products for health-conscious consumers.

hempSMART™ offers a number of different products within a wide range of delivery systems, such as its capsule-based formulations hempSMART™ Brain, a patent-pending nootropic product designed to support natural brain function; and hempSMART™ Pain, which is formulated with a blend of premium full-spectrum CBD and botanical supplements designed for pain associated with physical activity.

The company also offers sublingual CBD tinctures to customers including hempSMART™ Full-Spectrum Drops and their natural pet supplement hempSMART™ Pet Drops with advanced bioavailability.

hempSMART™ has also expanded upon its established line of products by offering topical products such as hempSMART™ Pain Cream, which is designed to provide temporary relief and soothe sore, aching muscles and joints. The company also launched a new cosmetic product, hempSMART™ Face, a CBD facial moisturizer that has been designed to refresh, replenish and restore skin cells on the face.

MCOA’s hempSMART™ CBD consumer products are sold at www.hempsmart.com.

Hemp Cultivation

In what appears to be a vertically integrated business strategy, MCOA entered into a joint venture with Global Hemp Group Inc. (OTC: GBHPF) to launch multiple industrial hemp cultivation projects in the legal marijuana states of the U.S. and in Canada. The first is a 125-acre industrial hemp cultivation project in northeast New Brunswick. The project is well under way with objectives of promoting hemp farming and attendant year-round jobs.

A certified professional agronomist, Joan Parker-Duivenvoorden, has been hired to manage the project. She has over 15 years of experience with the Nova Scotia Department of Agriculture and with the New Brunswick Soil and Crop Improvement Association, which will prove invaluable as the project expands to encompass and employ over 50 farmers.

Planting has been completed on the first 77 acres, and the remaining 48 acres will be seeded soon. Drying equipment is being evaluated to process the hemp after harvest, and management is already in discussions with several potential processing partners for extraction of cannabinoids. Once all the licenses have been acquired for importing and manufacturing finished CBD products, the New Brunswick site could easily serve as a distribution center for MCOA’s hempSMART™ subsidiary.

In another joint venture with Global Hemp Group, MCOA is also developing Covered Bridge Acres, a high-yielding CBD hemp cultivation project in Oregon. Operations at the farm are well under way. The project will utilize both traditional outdoor cultivation and what will be over 19,296 square feet of greenhouses.

“Our evolving project in Scio, Oregon, highlights the quality of the team in place as they continue to lean on their many years of experience cultivating hemp. Activities such as these will help to secure the raw oil that we will need for our hempSMART brand of CBD infused products,” stated Donald Steinberg, MCOA’s CEO.

The Takeaway

With rapidly expanding retail distribution and burgeoning, diversified hemp cultivation programs underway, MCOA is fast approaching the vertical integration that typically impacts bottom lines and drives shareholder value.

Other companies already operating in the CBD space include:

Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) grows and harvests hemp on an industrial scale and then processes it to extract cannabidiol (CBD) for worldwide distribution. The company pioneered the commercialization of 99 percent-plus pure, pharmaceutical-grade cannabinoids, micro-encapsulations and nanotechnology for consumable and topical skin care products.

CV Sciences (OTC: CVSI) operates in two business segments. The company’s drug development division develops and commercializes novel therapeutics utilizing synthetic CBD. Its consumer product division manufactures, markets and sells plant-based CBD products to a range of market sectors.

Medical Marijuana (OTC: MJNA) develops, distributes and sells hemp oil that contains naturally occurring cannabinoids, including CBD, and other products containing CBD oil. The company sells its hemp-derived CBD products through its distribution subsidiaries. The company was among the first to bring hemp-based CBD oil products to market in the United States.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) out-licenses its patented delivery technology, which lowers dosing of lipophilic active molecules and enhances their effectiveness. The company’s technology increases intestinal absorption rates, speeds delivery to the bloodstream, and masks tastes for orally administered bioactive molecules including cannabinoids, vitamins, NSAIDs, nicotine and other molecules.

Together, MCOA and these companies weave a tapestry of industry, innovation and intuitive concern for the communities they serve with nature-based hemp products that appear to be once again losing the stigma that has come from being marijuana’s staider sibling.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Dangers Lurking in Synthetic CBD Underscore Value of Quality Product

CannabisNewsWire Editorial Coverage: Dating back thousands of years, people have found ways to treat pain and other ailments with cannabidiol (CBD) oil which is harvested from the hemp plant. However, the natural healing properties of CBD are being jeopardized by the advent of man-made synthetic CBDs. These chemical analogs are dangerous imitations of plant-derived product, binding to human endocannabinoid receptors at astronomically larger quantities than natural cannabinoids. These designer drugs prompted the U.S. Centers for Disease Control and Prevention to issue a national health alert warning about synthetic cannabinoids. Shunning synthetics, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) provides consumers complete transparency and delivering only pure, plant-based 100% hemp-derived products through its hempSMART™ brand. While Medical Marijuana, Inc. (OTC: MJNA) and PotNetwork Holding, Inc. (OTC: POTN) market hemp-derived CBD products, some companies such as Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) and CV Sciences, Inc. (OTC: CVSI) utilize extraction techniques to produce isolated cannabinoid compounds for both commercial and/or research uses.

Surging Demand Creates Copy Cats

Hemp-derived CBD grew from a market category that didn’t exist five years ago to generating $190 million in sales in 2017. The U.S. industry is poised to reach $1 billion dollars in 2018, led by hemp-derived CBD, food, personal care and industrial products. Hemp Business Journal estimates the U.S. hemp industry will grow to a $2.6 billion market by 2022 with an estimated five-year CAGR of 25%.

In a recent article, “Fighting fakes: Hemp leaders on the dangers of synthetic CBD,” public health investigators issued warnings when 50 people were sickened after consuming synthetic CBD. What the epidemiologists found was that the products, while labeled CBD, did not contain CBD compounds. Instead, the products contained a synthetically produced cannabinoid.

CBD products are often mislabeled, both in how much CBD the products contain and where the CBD comes from. A study published in JAMA revealed that nearly 70% of online CBD marijuana extracts are mislabeled, some had extra CBD, some less, and some contained hidden CBDs. Blind testing found that only about 31% of the extracts tested contained the amount of CBD listed on the label.

Differentiated from Others

The company’s commitment to quality may differentiate Marijuana Company of America, Inc. (OTC:MCOA) from all others in the sector. MCOA uses the highest-quality sourced raw materials to produce the finest quality botanical supplements and topicals on the market. To ensure quality and transparency, the company’s hempSMART™ product line has been rigorously tested to validate its purity. Products developed by hempSMART are derived and formulated from industrial hemp containing naturally occurring CBD compounds that help support the body’s natural endocannabinoid system. All hempSMART™ products contain tested levels and clinically researched ingredients designed to meet and exceed consumers expectations.

The company is led by cannabis industry pioneer Donald Steinberg, MCOA’s CEO and an experienced veteran of the cannabis and industrial hemp industries. Steinberg founded the first marijuana company ever to trade on a U.S. stock market, and his extensive background and knowledge of the industry may give the company unparalleled insights into the global industrial hemp and cannabis markets.

Celebrated Family of Products

Derived from industrial hemp containing CBD compounds, MCOA’s hempSMART™ product line is among the finest quality of botanical supplements on the market. Scientifically driven, each of MCOA’s hempSMART™ products are created to ensure only the highest quality products reach discerning consumers. MCOA’s hempSMART™ CBD consumer products are researched, developed and sold at www.hempsmart.com.

The company recently re-launched its patent-pending wellness nootropic product hempSMART™ Brain, a “first of its kind” researched formulation for optimal brain function support, with 300mg of full spectrum CBD per bottle. HempSMART products also include full spectrum bioavailable CBD drops in form of a tincture containing a high concentration and potency of CBD, hempSMART ™ Pain capsules with a blend of premium CBD and botanical supplements, and hempSMART ™ Pain Cream with a synergistic combination of natural botanicals and full spectrum hemp extract to treat aching muscles and joints. In addition, the company now provides hempSMART™ Full Spectrum Pet Drops, exclusively designed for fur-bearing family members.

To virally expand sales, MCOA created its own unique hempSMART affiliate network marketing program. The affiliate marketing program provides a generous compensation plan to promote and sell hempSMART’s CBD consumer products in the United States. Advocates of hempSMART’s CBD products make the best ambassadors and the sales model lends itself to rapid global expansion.

Diversified Opportunity

In addition to the research and development of hemp-based consumer products, MCOA is strategically expanding its footprint across multiple facets of the hemp industry, building a portfolio of diversified investments and joint ventures to grow the company and potentially drive shareholder value.

The company recently provided updates on its 125-acre industrial hemp cultivation project in northeast New Brunswick with joint-venture partner Global Hemp Group Inc. (OTC: GBHPF). Planting on the first 77 acres is complete and the remaining 48 acres will be seeded soon. Drying equipment is being evaluated to process the biomass after harvest and management is in discussions with several potential processing partners for the material.

To target impulse buys in high traffic convenience stores, MCOA secured a 25% equity stake in Convenient Hemp Mart, LLC’s BeniHemp branded products. BeniHemp products will include topicals, tinctures, and edibles packaged in one-day, two-day, and 30-day supplies distributed to convenience stores, smoke shops, gas stations and similar small retail businesses.

Each owning 42.5%, MCOA and Global Hemp Group formed a joint venture, Covered Bridge Acres LTD., to develop a high yielding CBD hemp cultivation project in Oregon and committed to jointly invest a total of US$1.2 million into the project. A cornerstone of the project is the acquisition of a 109-acre agricultural property in Scio, Oregon. The property, located 70 miles south of Portland, is situated in the fertile Willamette Valley and has a history of hemp cultivation over the past two years. The farm is ideal for cultivating hemp as it contains a high level of organic matter in the soil and has an established irrigation infrastructure with sufficient water rights.

MCOA successfully raised $1 million in funding for Bougainville Ventures to construct and manage a turnkey state of the art cannabis cultivation and processing facility. The joint venture has completed the setup of 10,000 sq. ft. of greenhouse space and waiting for completion of inspection, the final step before commencing cultivation.

Active Companies Vying for Market Position

CV Sciences (OTCQB: CVSI) operates two business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing naturally occurring CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The company recently announced the June 7, 2018, publication of the toxicology and safety results of an extract from the base raw materials used in its PlusCBD Oil™ consumer products. The study, designed to investigate the safety of oral consumption of the company’s hemp CBD oil and to support a Generally Recognized as Safe (GRAS) Independent Conclusion, concluded that the test article was non-mutagenic, non-clastogenic and non-genotoxic.

Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is focused on pharmaceutical grade phytochemical compounds and is among industry leaders in the manufacture and development of consumer products. The company pioneered the commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for consumable and topical skin care products. Isodiol earlier this month entered into a binding agreement to acquire 51% of Round Mountain Technologies, LLC (“RMT”), a cultivator of organic hemp with operations in Nevada.

Medical Marijuana (OTC: MJNA), the first publicly traded cannabis company in the United States (founded by current CEO of Marijuana Company of America Don Steinberg), develops, distribute and sells hemp oil that contains naturally occurring cannabinoids, including CBD and other products containing CBD oil. In recent news, MJNA announced its favor on the Drug Enforcement Administration’s (DEA) recent statement on the legality of CBD — which further clarifies that some CBD products, such as hemp-derived CBD products, are legal to distribute throughout the United States and do not fall under the regulations of the Controlled Substances Act (CSA). Additionally, the company’s HempMeds® subsidiary reported the historic authorization of its Real Scientific Hemp Oil-X™ (RSHO-X™) CBD hemp oil product for import into Argentina.

PotNetwork Holding (OTC: POTN) is a holding company for its subsidiaries, First Capital Venture Co. that owns Diamond CBD, Inc., the maker of Diamond CBD oils. Diamond CBD researches, develops and markets hemp extracts that contain a broad range of cannabinoids and hemp derivatives. The company recently announced that Diamond CBD’s online sales increased 639% higher than the year prior. PotNetwork is in currently preparing to file with the SEC to become a fully reporting company.

With an estimated 25% compound annual growth rate, there’s little doubt the about the trajectory of the CBD market. As the market continues its rapid expansion and more people become aware of the dangers lurking in synthetic CBD, it seems reasonable that evermore consumers will gravitate toward high-quality natural CBD product. Companies like MCOA aim to answer that call.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Government Interest in Hemp Diversity Signals Strong Future for American Cannabis Industry

CannabisNewsWire Editorial Coverage: Recent U.S. government interest in ensuring industrial hemp supply signals a period of growth for the cannabinoid industry. Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) is contributing to this growth through new hemp cultivation projects in both Canada and the U.S., to support its hempSMART subsidiary. Cronos Group Inc. (TSX: CRON) (NASDAQ: CRON) is benefiting from a cross-border venture that gives it access to new scientific advances and has seen its shares reach top exchanges. Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) has secured government licensing needed to become one of Canada’s leading retailers, while acquiring a subsidiary company in Lesotho to cater to an international market. Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) has announced a new range of products that provide medical cannabis with a high concentration of active ingredients. OrganiGram Holdings Inc. (TSX-V: OGI) (OTCQB: OGRMF) has struck a deal for access to advanced extraction technology, while also gaining a license to export its products to Australia.

Senate Signals Support for Cannabis Seedbank

The United States government has a complicated relationship with cannabis. Since the mid-20th Century, it has clamped down on the use of the plant for any purpose, particularly during the “war on drugs” from the 1980s onward. Over the past decade, some states have legalized the farming and sale of the cannabis sativa plant either as medicine, as a recreational drug, or in the form of industrial hemp. But the federal government has remained reticent about shifting its stance.

It seems that perceptions are now changing. The Senate Appropriations Committee, one of the most powerful bodies in government, has acknowledged the growing importance of industrial hemp for American farmers and called for the creation of a hemp seed back. Half a million dollars will be spent ensuring that America has a genetically strong stock of high quality hemp seeds, to support both farmers and researchers.

Building Better Strains

While the committee’s plan to build up seed stocks is intended to support the national interest, some companies are already working on improving industrial hemp growth for reasons of self-interest. Developing a diverse range of strains, each tailored to different purposes, is important for these companies. Industrial hemp is often valued for the quality of its fibres and the medicinal cannabinoids that can be extracted from the plant and implementing better growing techniques can lead to improved crops yields.

Among the companies looking to create more efficient hemp yields is the Marijuana Company of America (MCOA Profile). A company with a diverse portfolio of investments and joint ventures in the cannabis and industrial hemp sectors, MCOA is involved in several projects intended to improve the plants available to producers and consumers.

Together with the Global Hemp Group, MCOA has launched a project to encourage industrial hemp cultivation in New Brunswick. Previous attempts to develop the industry in the region failed twenty years ago, but now the market for the product has grown. The aim is to develop an industrial cluster around the hemp crop, ensuring a market for farmers, consistent job opportunities, and to implement the proper structure to develop Hemp Agro-Industrial Zones, or HAIZ, projects in other areas.

Scientific testing to improve the growing process is an important part of HAIZ. This has been made possible through cooperation with the Canadian government’s Department of Aquaculture Agriculture and Fisheries (DAAF). The department will be contributing fertilizers to the project and carrying out fertility trials on reserved plots of land. Together with soil testing and crop rotation, this will help to develop more fertile organic growing conditions for the hemp.

With legalization of the extraction of cannabinoids from industrial hemp on the horizon, Canada is an important market for cannabinoid-based companies. Recreational use alone is expected to contribute $900 million to the industry, which already serves medical users in Canada. The work in New Brunswick gives MCOA an important foothold in this market.

More Facilities for a Growing Market

The collaboration with GHG is now taking place on both sides of the border, thanks to the establishment of a new industrial hemp project in Scio, Oregon. Once again, the companies are collaborating to create a facility that will push forward techniques in hemp cultivation while providing a steady profit.

The heart of this operation is a 109-acre property in the Willamette Valley, a fertile area with a recent history of successful cannabis cultivation. The site has soil rich in organic matter and established irrigation infrastructure, meaning that it is well set to support a new agricultural project. The use of high yield hemp clones will help to maximise the output of the project.

Multiple approaches to cultivation will feed into the Scio facility’s output. Traditional outdoor cultivation will take place alongside five greenhouses, which will provide over 19,000 square feet of indoor growing space. This will ensure a year-round supply of hemp.

As in New Brunswick, data collection and analysis will play an important part at the farm in Oregon. By checking on the performance of the growing techniques and the quality of the plants, the companies aim to support strains which are rich in cannabidiol (CBD), an active ingredient important in derivative products designed to support well-being.

A Growing Global Industry

The new project comes at a perfect time for MCOA. Demand for CBD is high thanks to the growing global market for cannabinoid-based products. A facility that can provide the companies with a steady supply of high-quality CBD plants will make it easier to take a substantial place in this expanding sector.

One of MCOA’s most important subsidiaries is hempSMART. This company develops and markets hemp-based wellness products that make use of cannabinoids, the active compounds that can be extracted from the hemp plant. HempSMART also aims to educate consumers on the possibilities offered by hemp, possibilities that the U.S. senate has started to acknowledge through its establishment of the new seed bank. Educators and health professionals are among the experts hempSMART has brought into its team, to make it more than just a source of wellness products.

With investments in everything from payment systems to cultivation facility rentals, Marijuana Company of America has built a broad base of innovative cannabis-related products.

More Companies Signal Strong Future

It’s a sign of the health of cannabis industry that MCOA faces competition from a number of companies, both in hemp production and in the wider cannabis market.

Cronos Group, Inc. (TSX: CRON) (NASDAQ: CRON) is one of the highest profile companies in this sector. In February 2018, it became the first pure play cannabis company traded on the Nasdaq, a sign of the interest in cannabis by mainstream investors. A recent upgrade of its shares on the Toronto Stock Exchange reflects the way that cannabis companies are solidifying their position, proving that they are here to stay. A recently announced cross-border venture with MedMen means that Cronos will benefit from scientific advances being made by the Los Angeles company, which prides itself on its research work.

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is becoming a leader in the cannabis retail field. Within Canada, it has established itself as a trusted company, being granted one of the first retail licenses in the province of Manitoba. This gives Canopy a strong starting point to sell to customers when recreational cannabis becomes legal in Canada later this year. Further afield, it recently acquired a cannabis company in the Kingdom of Lesotho. This will provide access to an African market largely ignored by western cannabis companies. It will also let the company grow medical cannabis in ideal conditions, with 300 days of sunshine a year, excellent humidity, and great growing conditions for greenhouse grown cannabis.

One of the largest cannabis companies, Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) has recently expanded its activities to cover both the recreational and medical sectors. The company leans heavily on research to improve its sales, with the announcement in late May of a new range of high-THC content cannabis products. It has also made moves to expand its market reach over recent months, with the largest corporate acquisition in the history of the cannabis industry in the form of the purchase of CanniMed, as well as a supplier agreement with Shoppers Drug Mart.

OrganiGram Holdings Inc. (TSX-V: OGI) (OTCQB: OGRMF) is looking beyond the American market. The company has recently been granted a license to export cannabis to Australia. This will introduce OrganiGram’s product to a new territory through a deal with a licensed Australian medical cannabis dealer. Organigram’s success will be further bolstered by a recent deal with TGS Colorado, a company with expertise in extract technology. This will provide Organigram with access to best-in-class technologies, products, and designs with which to make the most of its expanding cultivation base.

Increasing government backing, combined with advances in cultivation and technology, ensures that there’s a healthy future for all varieties of cannabis, from medical marijuana to industrial hemp.

For more information about Marijuana Company of America, please visit Marijuana Company of America (MCOA).

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Diversity Leads to Growth in Flourishing Cannabinoid Industries

CannabisNewsWire Editorial Coverage: The cannabis industry is about more than medicine and recreational drugs. Whether selling hemp-derived textile and construction products or providing resources to support cannabis growers, companies are now accessing the market in a variety of ways. Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) is developing hemp-based wellness products and cultivating industrial hemp on a large scale in Canada and the United States. Scotts Miracle-Gro Company (NYSE: SMG) is selling hydroponic equipment to legal cannabis growers and has recently made a significant acquisition in this area. Cronos Group, Inc. (TSX: CRON) (NASDAQ: CRON) has used its success to become the first pure play cannabis company traded on Wall Street and in Canada was uplisted to reach the Toronto Stock Exchange. PotNetwork Holding, Inc. (OTC: POTN) has fostered a range of subsidiaries whose diverse products include cannabinoid wellness products. In addition, companies such as AbbVie, Inc. (NYSE: ABBV), which already has a cannabis-based drug on the market, may be ahead of the game as the industry expands and evolves moving forward.

A Diverse Industry

A lot of attention is currently on the medical and recreational potential of the cannabis industry. The huge sums of money already spent on the life-changing promise of medical marijuana have pushed these areas to center stage. But while they are undoubtedly an important part of the sector, they do not illustrate the whole picture involving industrial hemp’s nationwide come back.

Much of the growth in the hemp industry is in subsidiary services and other uses for the plant’s products. Hemp – a variety of cannabis that does not contain its siblings’ intoxicating potential – is being grown for use in food, fibers and even building materials, all without getting anyone high. Landlords, compost manufacturers and engineering companies are finding ways to support and profit from the changing market. Even research into active ingredients involving cannabinoids is shifting away from THC, the chemical that gets marijuana users high, and toward the potential uses of non-intoxicating cannabidiol (CBD), which can be obtained from hemp.

The result is a varied industry in which companies can flourish through variety instead of focusing on one sphere.

Careful Cultivation

Marijuana Company of America (OTC: MCOA) is making the most of this opportunity. Founded by two veterans of the cannabis industry, MCOA is building a portfolio of partnered companies working across the sector.

One of the company’s important assets is hempSMART™, a wholly-owned subsidiary of MCOA. The hempSMART brand is focused on producing and marketing wellness products including CBD derived from hemp. The hempSMART team makes use of the cannabinoid chemicals to provide a range of products that are useful and appealing to consumers.

Hemp products were worth at least $688 million in 2016 and are expected to be worth $1.8 billion by 2020. Ownership of hempSMART gives MCOA a place in this significant part of the sector, meaning that it is not dependent on federally illegal THC-laden cannabis products to grow and sustain its revenue streams.

As a newly emerging industry, cannabis faces a great deal of uncertainty over sales and income potential. This uncertainty creates investor opportunities as companies outperform expectations. But it also creates risks due to fluctuations in income. A cultivation project in Washington State is providing MCOA with a buffer against these risks.

Created as part of a joint venture with Bougainville Ventures Inc., the cannabis cultivation and processing facility at Oroville, Wash., covers 10,000 square feet of state-of-the-art growing space, which will eventually be expanded to 30,000 square feet. Rather than using the site to grow its own products, MCOA is renting out the facility to a growing company, which is expected to begin work there this month. The rent from the facility ensures a stable source of income for MCOA — derived from cannabis cultivation but not prone to its uncertainties. By providing this facility, the company is also supporting the growth of the cannabis sector, creating a market for such properties and for its own related products.

Preparing for the Canadian Market

Making the most of the possibilities offered by cannabis isn’t just about diverse products, it’s also about diverse markets. For any company working in North America, Canada is one of the most important markets currently and MCOA is preparing to enter that market.

Canada is already a significant market for industrial hemp-derived products and medicinal cannabinoids. Legislation due to come into force later this year will legalize the extraction of cannabinoids for all potential uses which will make Canada one of the largest markets for legal cannabinoids in the world.

To make the most of this expected market growth, MCOA recently entered into a joint venture with Global Hemp Group, a Canadian company, to develop high-yield CBD hemp. Working on a 109-acre agricultural property in Scio, Oregon, the companies will use a dual-cultivation strategy with traditional outdoor cultivation alongside the year-round harvesting made possible by greenhouses. Cultivation of plants has already begun, and work has started to construct five new greenhouses to ensure substantial year-round growing capacity.

The project team will be using data collection and analysis to check the performance of growing techniques and to develop hemp rich in CBD. This will help to ensure supplies of high-grade hemp for both companies’ products.

“Our evolving project in Scio, Ore., highlights the quality of the team in place as they continue to lean on their many years of experience cultivating hemp,” said Donald Steinberg, the CEO of Marijuana Company of America. “Activities such as these will help to secure the raw oil that we will need for our hempSMART brand of CBD infused products.”

Meeting Growing Demand

The Oregon facility is coming into play at a perfect time for MCOA. Demand for CBD is high due to the increasing number of manufacturers and products on the market. This is creating a shortage of high-quality CBD.

MCOA’s new farm will provide an ample source of hemp-derived CBD. With its tie-in to the Canadian industry, the company looks to be in a strong position to profit from the shortage in both the American and Canadian markets. MCOA seems to have placed itself as the right business at the right time to make the most of a shifting market.

With its range of facilities and partnerships, MCOA has already developed a broad hemp-related portfolio. By incorporating elements that are protected from market uncertainties alongside ones better positioned to make the most of change, the company may be on track to make the most of changes in the sector.

More Companies Target Cannabis

Plenty of other companies are also building their hopes of tapping into the same markets as MCOA.

A growing interest in growing things means cannabis is creating opportunities for companies already established in the agriculture and gardening sectors. Scotts Miracle-Gro Company (NYSE: SMG) has agreed to acquire Sunlight Supply, the United States’ leading distributor of hydroponics products, for $450 million in cash and stocks. The company’s largest-ever transaction will double its sales to cannabis growers, turning the lawn and gardening company into an important supplier to the medical and recreational drug sectors. Though hydroponics are used for other specialist plant-growing purposes, legalized cannabis is a critical new part of the market.

The increasing importance of the cannabis industry was heralded when Cronos Group, Inc. (TSX: CRON) (NASDAQ: CRON) became the first pure-play cannabis company traded on Wall Street. A major grower and seller of cannabis products, the Canadian company is set to profit from the growth of the industry in its native country. In a further sign of its healthy prospects, its shares in Canada were recently upgraded from the Toronto Venture Exchange to the Toronto Stock Exchange. Like MCOA, it is working across North America thanks to a cross-border venture with Los Angeles-based MedMen.

Others are using a similar model to MCOA, investing in a range of cannabis companies. PotNetwork Holding, Inc. (OTC: POTN) has developed a range of subsidiaries that contribute to an increasingly diverse industry. Its Diamond CBD, Inc. subsidiary is reaching into the $110 billion global pet care industry by creating CBD-based wellness products for pets.

Finally, traditional pharma AbbVie, Inc. (NYSE: ABBV) seems to be positioning itself in the industry so it can take advantage of potential future growth and opportunities. The company already has a cannabis-based drug on the U.S. market. FDA-approved Marinol helps alleviate nausea or vomiting for chemotherapy patients, as well as helping AIDS patients who have lost their desire to eat.

From hydroponics to pet health and beyond, hemp-based cannabinoids are reaching into all corners of the economy and returning corporate profits.

For more information about Marijuana Company of America, please visit Marijuana Company of America (OTC: MCOA).

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

CBD Market Set for Huge Growth

CannabisNewsWire Editorial Coverage: In a fragile economic world, industries with significant growth forecast are certain to catch the eye of savvy investors looking for just the right place to be. Recent reports indicate that the cannabidiol (CBD) market is estimated to grow by 700 percent by 2020, and a report by market intelligence firm Hemp Business Journal projects that the CBD market will grow to $2.1 billion by 2020 (http://cnw.fm/7iczS), an astronomical jump in value compared to last year’s CBD market of $202 million. This news bodes well for hemp-focused companies such as Marijuana Company of America (OTC: MCOA) (MCOA Profile), whose hempSMART™ brand will be among the first CBD products to be marketed on a mass national TV commercial. Growth in hemp-based products is only a piece of the cannabis industry puzzle. The entire legal cannabis industry is expected to hit $57 billion by 2027, with recreational marijuana use making up 67 percent of that and medical marijuana use taking up the remaining 33 percent. Other companies positioning themselves to take advantage of this incredible growth include AbbVie, Inc. (NYSE: ABBV), CV Sciences, Inc. (OTCQB: CVSI), KushCo Holdings, Inc. (OTCQB: KSHB), and Aurora Cannabis, Inc (OTCQX: ACBFF).

Capitalizing on the Power of CBD

Studies show that cannabidiol (CBD) possesses an array of therapeutic benefits, including antioxidant and neuroprotective properties. One of more than 85 cannabinoids identified in marijuana and hemp, CBD is typically used for health reasons and, unlike the more widely recognized compound tetrahydrocannabinol (THC), is not psychoactive, meaning it doesn’t cause a high. CBD products can be derived from industrial hemp plants or marijuana plants.

Marijuana Company of America (MCOA Profile), an industrial hemp company, has capitalized on the power of CBD through its product research and development of legal hemp-based consumer products under the hempSMART brand, which targets general health and well-being. The products, which include drops and creams, are formulated to produce the finest botanical supplements on the market, derived from industrial hemp containing CBD compounds that help support the bodies endocannabinoid system.

A National Market Strategy and TV Commercial

 Earlier this month, MCOA announced (http://cnw.fm/WxIg1) that it had engaged Kim Castle of Verve Integrative to create a market strategy and manage a direct response television ad campaign to promote its hempSMART product line. Initially, hempSMART will be working with Verve Integrative to develop a market strategy and television commercial for its hempSMART Full Spectrum Pet Drops, which will air on cable networks this summer. The commercial spot will have featured placement on the official ecommerce site of a popular direct-response TV company and will be broadly promoted on integrated social media outlets.

“We are very pleased to partner with hempSMART on their journey to bring such thoughtful and well-developed products to the people who need natural relief and enhanced health solutions. I wish hempSMART™ Pet Drops were available to support my cherished dog when we were going through a health challenge together,” said Castle, who, along with her team, bring more than 25 years of experience in many variations of media strategy, development and production. Their clients include Disney, GM, ABC, Paramount, and Grey Group.

The team specializes in multipoint story experiences designed to educate, entertain and endorse while mirroring the human mind’s process of solving a problem, thereby supporting consumers in making emotional and logical product conclusions. Castle’s experience provides an invaluable edge to the hempSMART marketing campaign. Castle has also been an outspoken advocate of CBD as an alternative to traditional products currently on the market.

MCOA CEO Donald Steinberg noted that “Kim’s experience gives us an excellent opportunity to greatly expand the marketing strategy for the hempSMART brand and product line. We are honored that the hempSMART product line will be managed by her and the Verve Integrative team. We look forward to the new television commercial airing this summer.”

Pet Supplement Market Expanding

MCOA just launched its hempSMART Full Spectrum Pet Drops in February. The new specially formulated product contains naturally occurring CBD derived from hemp seed oil, full spectrum hemp extract, and fractionated coconut oil, along with a rich bacon flavor.

Sales of natural pet supplement sales nearly doubled between 2008 and 2011, and with an increasing focus on pet health, the market for pet supplements is projected to show significant and continuing expansion (http://cnw.fm/66NhV). Estimates show that U.S. retail sales of pet supplements and nutraceutical treats will grow 3 to 5 percent annually, bringing the market to almost $1.6 billion. Globally, the pet supplement market is also expected to experience tremendous growth.

Steinberg said, “Our new hempSMART product is a natural option for pet owners who care about supporting their animals’ healthy energy levels as well as optimizing their health. Our hempSMART product line will continue to expand to other popular areas of consumer interest to give our affiliates what they need to succeed.”

Wellness Environment Shifting toward CBD

The wellness industry is growing rapidly, generating an estimated $3.72 trillion annually (http://cnw.fm/d3Zs5). In addition, the attitude in the wellness environment is shifting regarding premium quality cannabinoid products. MCOA is one of the prominent companies working to give consumers access to technological innovations and the highest quality hemp-derived products.

Specifically designed to support normal bodily functions such as energy, flexibility, and overall wellness, hempSMART products are only the beginning for MCOA and its hempSMART division. MCOA is committed to find, test, and deliver the finest natural ingredients focused on wellness and personal care combined with the added benefits of hemp-based cannabinoids.

In addition to dedicating itself to the development of CBD-based nutritional products, MCOA is focused on educating and empowering consumers to learn about and become part of the hemp movement, thus allowing its customers to benefit from some of the world’s most innovative hemp products. The company is also dedicated to supporting the resurgence of green sustainable hemp-based products and technologies that have a positive effect on the environment.

Others Positioning in the Market

MCOA isn’t the only company deeply committed to making its presence felt in the burgeoning hemp and cannabis industries.

AbbVie (NASDAQ: ABBV) is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. With a cannabis-based drug already available on the market, pharmaceutical company AbbVie, is ahead of the pack in this industry. Its FDA-approved Marinol is approved for chemotherapy-induced nausea and vomiting and anorexia, and the drug may also help AIDS patients who have lost their desire to eat.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD, and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The company’s PlusCBD Oil™ has achieved immense success since the launch of its brand of dietary supplements. The brand is currently being sold in approximately 1,300 health food stores and continues to grow its shelf presence in various retail outlets across the country. “It’s evident that hemp-derived CBD products are doing better and growing faster than almost every other category in the supplement industry, and it’s been a long time since we’ve seen a supplement trend truly demonstrate demand in such an immense fashion,” said Stuart Tomc, vice president of human nutrition and spokesperson for CV Sciences. “There are no barriers to acceptance as the idea of hemp-derived CBD is finally ripe. Consumers are embracing hemp-derived CBD.”

The premier packaging company in the rapidly growing legal, regulated marijuana industry, KushCo Holdings, Inc. (OTCQB: KSHB) is a dynamic sales and distribution platform that provides packaging, supplies, vaporizer products, hydrocarbons, accessories, and branding services to cannabis manufacturers, processors and retailers. Founded in 2010, Kush Bottles now has 12 facilities throughout the United States, a sales presence in every major cannabis market, and strives to be the go-to supplier and thought leader for businesses in the cannabis industry. KushCo recently announced that it had partnered with MainStem, a technology-based ancillary product distribution company for the regulated cannabis industry, to be the inaugural partner for MainStem’s Vendor Program (MVP).

An industry leading producer of medical cannabis, Aurora Cannabis, Inc (OTCQX: ACBFF) operates a 55,200-square-foot, state-of-the-art production facility in Mountain View County, Alberta, and a second 40,000-square-foot, high-technology production facility in Pointe-Claire, Quebec. In January 2018, Aurora’s 800,000 square-foot-flagship cultivation facility located at the Edmonton International Airport was licensed. When at full capacity, this facility is expected to produce over 100,000 kg per annum of cannabis. Aurora is also completing a facility in Lachute. In addition, the company just announced its intention to acquire MedReleaf Corp. (TSX: LEAF). This proposed transaction will bring together two of Canada’s premier cannabis companies with fully aligned strategic visions and production philosophies, as well as complementary assets, distribution networks, products, and capabilities. The combined company will meet what Aurora and MedReleaf management teams consider to be the critical success factors in the industry, creating a powerful platform for accelerated growth on a global scale.

For more information about Marijuana Company of America, please visit Marijuana Company of America (MCOA).

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.